Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A cancer protein’s journey to cell membrane

11.04.2014

KRas moves between various membranes within the cell, so that it is available in a sufficient quantity at its actual destination

The cancer protein KRas is a factor in the development of several types of cancer. Mutated KRas, for example, can be found in a large number of all tumour cells in patients with pancreatic cancer. It sits on the inner leaflet of the cell membrane and relays signals into the cell’s interior.


Distribution of the cancer protein KRas in a cell.

© M. Schmick

Scientists at the Max Planck Institute of Molecular Physiology in Dortmund have now discovered why KRas is almost exclusively found at the cell membrane when observed under the microscope. Apparently, the protein is not specifically sent to the cell membrane after it is formed, but is also located on other membrane systems within the cell for its entire life span.

In order for it to be transported by special transport vesicles from the vicinity of the cell nucleus to the cell membrane, the solubilising factor PDEδ and its antagonist Arl2 must be active. Without the two of them, KRas would spread to cell membranes. The researchers can use their results to better understand how deltarasin works, which is a potential anti-cancer drug that they have developed.

The protein KRas acts as a molecular switch in relaying signals to the cell’s interior. Among other things, such signals control cell growth. In order for KRas to be able to function correctly, it must remain on the inner leaflet of the cell membrane for a sufficient period of time. Its water-insoluble lipid anchor helps it to achieve this.

However, this also anchors the protein to other intracellular membranes. KRas therefore has an area of positive charges near this lipid anchor. Similar to a polystyrene ball in a plastic bag, the electrostatic interaction of these positive charges with the negatively charged inner leaflet of the cell membrane reinforces the lipid anchoring.

But even lipid anchor and positive charges are not enough to ensure that KRas is permanently enriched at the cell membrane. According to the results obtained by the researchers in Dortmund, many KRas molecules would still be lost on the available surface of the rest of the membrane systems in the cell, which is 200 times bigger than that of the cell membrane. Using complex computer simulations, the scientists evaluated data from fluorescence microscopy experiments and tracked the movement of KRas on its journey though the cell.

“Our results show that the cell membrane is by no means the final destination of KRas, which must only be encountered once. Instead, KRas constantly and unspecifically re-distributes to the various membrane systems of the cell and must then be concentrated on the inner leaflet of the cell membrane via a continuous cycle,” explains Malte Schmick from the Max Planck Institute of Molecular Physiology.

In the first step of this cycle, the soluble protein PDEδ shields the lipid anchor of KRas like a glove, thus making KRas water-soluble. This prevents KRas from simply finding some arbitrary membrane. Swimming in the cytoplasm, KRas can thus explore the cell. When it gets close to the nucleus of the cell, the activity of the protein Arl2 removes this glove. KRas is now insoluble in water again and can be trapped on membranes and transported back to the cell membrane by vesicles.

The cell therefore does not have a unique targeting system for KRas, which sends it exclusively to the cell membrane. Instead, the protein redistributes to all membranes and is repeatedly sorted from the wrong membranes to the correct one. “Each KRas molecule lives for several hours before the cell disassembles it again. After seven minutes, half of all KRas molecules are internalized from the cell membrane to be subjected to the cycle and sent back to the cell membrane. In total, each KRas molecule travels for approximately 20 minutes before it reaches the cell membrane again,” says Schmick.

The results obtained by the scientists in Dortmund pave the way for the development of new cancer drugs. This is due to the fact that KRas is modified in many forms of cancer to such an extent that it is permanently active and the cell can no longer switch it off. One-third of all tumours contain cells with mutations of Ras proteins. In the case of intestinal cancer for example, mutated KRas prevents successfully using antibody treatment against epidermal growth factor receptors (EGFR).

“We can now develop active agents that reduce the enrichment of mutated, permanently active KRas at the cell membrane,” explains Philippe Bastiaens, Director at the Max Planck Institute in Dortmund. In 2013, he worked with colleagues Herbert Waldmann and Alfred Wittinghofer to develop an inhibitor, known as deltarasin, to block the PDEδ solubilizing activity. Initial experiments on mice have shown that the active agent considerably slows the growth of tumours. Even though scientists had been aware of the relevance of PDEδ for a while, this work now explains for the first time the mechanism by which deltarasin prohibits KRas from being enriched at the cell membrane and causes it to be distributed throughout the entire cell.

Contact 

Prof. Dr. Philippe Bastiaens
Max Planck Institute of Molecular Physiology, Dortmund
Phone: +49 231 1332-200
Fax: +49 231 1332-299
Email:philippe.bastiaens@mpi-dortmund.mpg.de
 
Dr. Peter Herter
Max Planck Institute of Molecular Physiology, Dortmund
Phone: +49 231 133-2500
Fax: +49 231 133-2599 

Original publication

 
Malte Schmick, Nachiket Vartak, Björn Papke, Marija Kovacevic, Dina C. Truxius, Lisaweta Rossmannek, Philippe I.H. Bastiaens
KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport
Cell, 10 April 2014

Prof. Dr. Philippe Bastiaens | Max-Planck-Institut

Further reports about: Molecular Physiology anchor experiments factor signals tumours vesicles

More articles from Life Sciences:

nachricht How longhorned beetles find Mr. Right
28.05.2015 | University of Arizona

nachricht Protein scaffold
27.05.2015 | Okinawa Institute of Science and Technology (OIST) Graduate University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Solid-state photonics goes extreme ultraviolet

Using ultrashort laser pulses, scientists in Max Planck Institute of Quantum Optics have demonstrated the emission of extreme ultraviolet radiation from thin dielectric films and have investigated the underlying mechanisms.

In 1961, only shortly after the invention of the first laser, scientists exposed silicon dioxide crystals (also known as quartz) to an intense ruby laser to...

Im Focus: Advance in regenerative medicine

The only professorship in Germany to date, one master's programme, one laboratory with worldwide unique equipment and the corresponding research results: The University of Würzburg is leading in the field of biofabrication.

Paul Dalton is presently the only professor of biofabrication in Germany. About a year ago, the Australian researcher relocated to the Würzburg department for...

Im Focus: Basel Physicists Develop Efficient Method of Signal Transmission from Nanocomponents

Physicists have developed an innovative method that could enable the efficient use of nanocomponents in electronic circuits. To achieve this, they have developed a layout in which a nanocomponent is connected to two electrical conductors, which uncouple the electrical signal in a highly efficient manner. The scientists at the Department of Physics and the Swiss Nanoscience Institute at the University of Basel have published their results in the scientific journal “Nature Communications” together with their colleagues from ETH Zurich.

Electronic components are becoming smaller and smaller. Components measuring just a few nanometers – the size of around ten atoms – are already being produced...

Im Focus: IoT-based Advanced Automobile Parking Navigation System

Development and implementation of an advanced automobile parking navigation platform for parking services

To fulfill the requirements of the industry, PolyU researchers developed the Advanced Automobile Parking Navigation Platform, which includes smart devices,...

Im Focus: First electrical car ferry in the world in operation in Norway now

  • Siemens delivers electric propulsion system and charging stations with lithium-ion batteries charged from hydro power
  • Ferry only uses 150 kilowatt hours (kWh) per route and reduces cost of fuel by 60 percent
  • Milestone on the road to operating emission-free ferries

The world's first electrical car and passenger ferry powered by batteries has entered service in Norway. The ferry only uses 150 kWh per route, which...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International symposium: trends in spatial analysis and modelling for a more sustainable land use

20.05.2015 | Event News

15th conference of the International Association of Colloid and Interface Scientists

18.05.2015 | Event News

EHFG 2015: Securing health in Europe. Balancing priorities, sharing responsibilities

12.05.2015 | Event News

 
Latest News

More densely populated urban areas call for more urban quality

28.05.2015 | Architecture and Construction

The Arctic: Interglacial period with a break

28.05.2015 | Earth Sciences

New transregional special research field at the universities of Stuttgart and Constance

28.05.2015 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>